Navigation Links
Groups Issue New Dementia Drug Guidelines
Date:3/4/2008

Review finds little difference in effectiveness of 5 drugs currently available

TUESDAY, March 4 (HealthDay News) -- There's no proof that any one of the five drugs available in the United States to treat dementia is better than the others, says an American College of Physicians (ACP) and American Academy of Family Physicians (AAFP) committee that just issued a new guideline on drug treatment of dementia.

The committee reviewed published studies for outcomes such as cognition, global function, behavior/mood, and quality of life/activities of daily living. But the committee said it found only limited high-quality scientific evidence about the effectiveness of the drugs and therefore developed the following cautious recommendations:

  • The decision to use approved drugs for dementia should be based on an individualized patient assessment.
  • The choice of drugs should be based on tolerability, adverse effect profile, ease of use, and cost.
  • There's an urgent need for more clinical research to improve knowledge about the clinical effectiveness of drugs treatment for dementia.

The committee recommended the following kinds of research:

  • Evaluate the effectiveness of drug therapy for dementia and assess whether treatments affect key outcomes, such as institutionalization.
  • Evaluate the appropriate duration of therapy.
  • Head-to-head testing of drugs.
  • Test drugs in combination therapy.

The guideline are published in the March 4 issue of the Annals of Internal Medicine.

Currently, there are five FDA-approved drugs for treatment of dementia. These include four acetylcholinesterase inhibitors -- donepezil (Aricept), galantamine (Razadyne, Reminyl, Nivalin), rivastigmine (Exelon), and tacrine -- and one neuropeptide-modifying agent -- memantine (Mamenda).

While these drugs may improve symptoms or slow disease progression, they don't cure dementia or repair brain damage.

"Doctors, patients and family caregivers desperately want information on how to treat this disease," Dr. Amir Qaseem, senior medical associate in the ACP's Clinical Programs and Quality of Care Department, said in a prepared statement. "It is disheartening to find that all we have to work with is these five drugs, and the evidence on these is scant. Consider that in 50 years, one in 45 Americans will suffer from Alzheimer's disease. This is a huge problem."

Most of existing studies of the five approved dementia drugs focused on statistical significance of changes, but clinically important improvement is what matters to patients, caregivers and doctors, the committee noted.

"More research is warranted, because the available evidence concerning these pharmaceuticals' effects on quality of life is mixed, and the clinical significance of many of the findings is questionable," Dr. Kenneth G. Schellhase, an AAFP representative on the committee, said in a prepared statement. "In addition, the duration of existing trials was usually less than one year, providing insufficient information to determine the optimal length of treatment, and few trials compare one drug directly with another."

More information

The Family Caregiver Alliance has more about dementia.



-- Robert Preidt



SOURCE: Annals of Internal Medicine, news release, March 3, 2008


'/>"/>
Copyright©2008 ScoutNews,LLC.
All rights reserved  

Related medicine news :

1. Atria Bills Get Support From Assisted Living Residents, Family Members, Senior Groups
2. Closer Analysis Shows Consumer Groups Make Gains in Stem Cell Patent Challenges Against WARF; Appeal Still Planned Against Narrowed Claims
3. Hospital Groups United in Opposition to Charity Care Cuts
4. Consumer Groups Will Continue to Press Stem Cell Patent Challenge
5. Alzheimers Foundation of America Awards Grants to Local Groups Nationwide
6. Health Groups Launch Ad Campaign Supporting 70-Cent Increase in Kentucky Cigarette Tax
7. Family, Friends and Support Groups Add Picture Messaging to Inspire and Motivate - Anywhere, Anytime
8. Nations Leading Preventive Health Groups Seek to Save Lives by Transforming Americans Approach to Health
9. Bush Budget Puts Future of Health Care for All Children in Jeopardy, According to National Pediatric Groups
10. Former FTC Attorney Christine White Joins Crowell & Morings Health Care and Antitrust Groups
11. Engaging 2008 Debate, Key Long Term Care Advocacy Groups Offer New Plan to Strengthen Nations Long Term and Post-Acute Care Delivery System
Post Your Comments:
*Name:
*Comment:
*Email:
Related Image:
Groups Issue New Dementia Drug Guidelines
(Date:2/12/2016)... ... February 12, 2016 , ... Coco Libre, the maker of coconut water ... LA GRAMMY’s Style Lounge Event. Coco Libre will offer musicians and celebrities the company’s ... big event. The invitation-only gifting suite, held this year at the W Hollywood Hotel, ...
(Date:2/12/2016)... ... February 12, 2016 , ... Fisher House Foundation Chairman and ... J. Lee, Nevada Military Support Alliance president Scott Bensing, and Peggy Kearns Director, VA ... Southern Nevada Healthcare System. This will be the first Fisher House in Nevada, ...
(Date:2/12/2016)... ... February 12, 2016 , ... ... Pittsburgh metro area, celebrates the beginning of the latest charity campaign in their ... skills through art. Donations to this worthy cause are currently being accepted at: ...
(Date:2/12/2016)... ... February 12, 2016 , ... ... Care.” , The print component of “Revolutionizing Cancer Care” is distributed ... York, Washington DC/Baltimore, and Seattle, with a circulation of approximately 250,000 copies and ...
(Date:2/12/2016)... Highlands Ranch, Colo. (PRWEB) , ... February 12, 2016 , ... ... particularly over the past 35 years. A president has access to health and wellness ... leader of the free world, no single individual has a schedule as frenetic as ...
Breaking Medicine News(10 mins):
(Date:2/12/2016)... Feb. 12, 2016  Sequent Medical, Inc. announced today ... to evaluate the safety and effectiveness of the WEB™ ... ruptured intracranial aneurysms.  Prof Laurent Spelle , MD, ... Paris, France and Principal Investigator of ... France and Germany.  Although patients with ...
(Date:2/12/2016)... , Feb. 12, 2016  Aralez Pharmaceuticals Inc. (Nasdaq: ... announced the Company will ring the Nasdaq Closing Bell ... New York at 4:00 p.m. ET on ... Aralez. Adrian Adams , will perform ... 3:50 to 4:00 p.m. ET.  A live webcast will ...
(Date:2/12/2016)... February 12, 2016 ... auf den ungedeckten medizinischen Bedarf bei Lungen- ... seines klinischen Forschungsprogramms bekannt. Das Programm, das ... Verbesserungen ihrer respiratorischen Funktionen und anderer klinischer ... ein Medizintechnikunternehmen, das sich auf den ungedeckten ...
Breaking Medicine Technology: